-
Bearing Responsibility and Taking on Challenges—ILROG Leading the Future of the Lymphoma Field
With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case…
-
ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer
In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one…
-
ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer
In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one…
-
ASCO China Voice丨Professor Nanlin Li: Efficacy and Safety Data of RC48 for Neoadjuvant Therapy in HER2-Positive Breast Cancer
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will take place in Chicago from May 31 to June 4. Led by Professor Nanlin Li from Xijing Hospital of the Air Force Medical University, a single-center, single-arm phase II clinical study focused on the efficacy and safety of the HER2-targeting antibody-drug conjugate (ADC) RC48…
-
Big Data, New Discoveries—The Key Role of Radiation Therapy in MZL and MALT Treatment
With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case…
-
2024 ESMO BC丨New Targeted Therapy Options for HR+/HER2- Breast Cancer
Several studies presented at the 2024 ESMO Breast Cancer (ESMO BC) conference demonstrated the potential efficacy of new CDK4 selective inhibitors and the lasting benefits of pan-AKT inhibitors. The latest results from the first human study of a new CDK4 selective inhibitor were presented at the 2024 ESMO BC conference (May 15-17, Berlin). This study…
-
2024 EBMT Review | Professor Jun Ma : CARTITUDE-4 Study—Efficacy and Safety of Ciltacabtagene Autoleucel (cilta-cel)
From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over…
-
Professor Donglu Zhao: Research Progress in Burkitt Lymphoma Treatment | 2024 Nanjing Lymphoma Forum
The “2024 Nanjing Lymphoma Forum” was held in Nanjing from May 11-12, 2024. The conference, primarily conducted through in-person exchanges, invited renowned experts in the field of lymphoid tumors from both domestic and international arenas. Through lectures, case discussions, and other forms of interaction, the forum focused on the latest achievements and advancements in the…
Connecting Medical Expertise through Media